RxDoctor Payments Data

Sreekumar Nair, MD

Psychiatry · Santa Cruz, CANPI 1104848191

Payments from drug & device makers

$2,858in general payments, 2019–2025

Across 31 payments — averaging $92.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$1K
  • Alkermes, Inc.$749
  • AbbVie$440
  • Neurocrine Biosciences, Inc.$125
  • Indivior Inc.$119
  • Otsuka America Pharmaceutical, Inc.$118
  • plus $171 from 2 others

What the payments were for

  • Food & beverage$2,858100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,858 in reported general payments places this provider in the 85th percentile of 4,954 psychiatry providers in California.

See all psychiatry providers in California

Medicare billing

Part B allowed, 2024
$23,146
Medicare patients
43
Services billed
233

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate40$124,754
Abilify MaintenaAripiprazole14$41,492
RybelsusSemaglutide13$13,153
Clozapine OdtClozapine11$12,362
Olanzapine139$11,261
Chlorpromazine Hcl28$10,354
Clozapine72$4,657
Divalproex Sodium ErDivalproex Sodium26$4,131
Olanzapine OdtOlanzapine30$3,091
Quetiapine Fumarate36$3,082
Divalproex Sodium48$2,771
Tolterodine Tartrate ErTolterodine Tartrate12$2,060
Haloperidol28$1,892
Tenofovir Disoproxil Fumarate12$1,620
Oxybutynin Chloride ErOxybutynin Chloride18$1,534

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$1,136$124,75440 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$118$41,49214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,954 psychiatry providers in California.

Other psychiatry in Santa Cruz

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →